Accessibility Menu
Quest Diagnostics logo

Quest Diagnostics(NYSE) DGX

Current Price$207.60
Market Cap$22.90BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1996)+8,272%
5 Year+65%
1 Year+26%
1 Month+7%
Quest Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 206.842026-07-21
Quest Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.41%USD 206.002026-07-14
1 month+6.5%USD 194.212026-06-18
3 month+1.8%USD 203.172026-04-22
Year to date+20.75%USD 171.292025-12-31
1 year+26.45%USD 163.582025-07-21
3 year+51.95%USD 136.132023-07-21
5 year+65.22%USD 125.192021-07-22
Since inception+8,271.73%USD 2.471996-12-17

Quest Diagnostics Financials at a Glance

Market Cap

$22.90BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$11.28B

Net Income (TTM)

$1.02B

EPS (TTM)

$9.07

P/E Ratio

22.82

Dividend

$3.32

Beta (Volatility)

0.36 (Low)

Price

$207.60

Volume

28,007

Open

$208.16

Previous Close

$206.84

Daily Range

$205.90 - $208.84

52-Week Range

$165.78 - $219.20

Estimated Earnings Date

Jul 23, 2026

DGX News

Cannabis greenhouse.

5 Best Marijuana Stocks for 2026 and How to Invest

Keith SpeightsJul 14, 2026
Doctor holding clipboard stands with virtual DNA double helix in the air near him.

Best Genomics Stocks for 2026 and How to Invest

Lyle DalyApr 18, 2026
maxresdefault (1)

Quest Diagnostics: A Solid Investment or a Risky Bet?

Motley Fool YouTubeSep 4, 2025
Foolcom-Featured.png

Quest Diagnostics Raises 2025 Guidance

Motley Fool Markets TeamJul 22, 2025
featured-earnings-leadership-highlights.png

Quest Diagnostics Boosts Its 2025 Outlook

Motley Fool Markets TeamJul 22, 2025
Person using a diagnostic health test

Why Quest Diagnostics Stock Was Blasting Higher Today

Eric VolkmanJan 30, 2025
GettyImages-1460419757-600x400-bf06395.jpg

Quest Diagnostics EPS Tops Predictions

Motley Fool Markets TeamJan 30, 2025
GettyImages-543357442.jpg

Quest Diagnostics EPS Beats Expectations

Motley Fool Markets TeamOct 22, 2024
Page 1

DGX: Motley Fool Moneyball Superscore

75

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Quest Diagnostics

Quest helps doctors and patients understand health through laboratory test results. They perform blood and tissue tests to help find and treat diseases. These services support about half of all physicians and hospitals in the United States.

What Quest Does

  • Diagnostic Information Services: Routine, non-routine, and advanced clinical testing including oncology and genetics; accounted for approximately 40% of revenue from health plans in 2025.
  • Advanced Diagnostics: Specialized tests for complex conditions like Alzheimer's disease and cancer; certain offerings in five clinical areas generated over $1 billion in revenue in 2025.
  • Diagnostic Solutions: Risk assessment services for life insurers and information technology tools for healthcare providers.
  • Employer Services: Workplace drug testing and employee wellness programs to help companies manage health costs and safety.

Growth and New Directions

  • Acquired Haystack Oncology in 2023 to add highly sensitive technology for detecting recurring cancer.
  • Launched a joint venture with Corewell Health in 2025 to perform laboratory testing in Michigan.
  • Purchased clinical testing assets from Fresenius Medical Care through Spectra Laboratories in 2025.
  • Acquired LifeLabs in 2024, expanding diagnostic and digital health services into the Canadian market.

Why Quest Stands Out

Quest maintains one of the largest clinical databases in the world with over 80 billion patient data points. This data allows the company to identify health trends and develop precise new tests through artificial intelligence and advanced automation.

The Recent Numbers

  • Revenue reached $11 billion in 2025, according to the annual report.
  • Net income was $245 million in Q4 2025, up 10.4% from Q4 2024.
  • Operating income rose to $391 million in Q4 2025, an 8.3% increase year-over-year.
  • The company served approximately half of the adult population in the United States over a three-year period.

Bottom Line

Quest has transitioned from a traditional lab provider into a data-driven healthcare partner. Its expansion into specialized genetic testing and digital health tools has diversified its role across the global medical landscape.

AI Generated • Apr 19, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

57,000

CEO

James E. Davis

Website

www.questdiagnostics.com

Headquarters

Secaucus, NJ 07094, US

DGX Financials

Key Financial Metrics (TTM)

Gross Margin

33.23%

Operating Margin

14.31%

Net Income Margin

9.08%

Return on Equity

14.11%

Return on Capital

11.38%

Return on Assets

6.14%

Earnings Yield

4.38%

Dividend Yield

1.61%

Payout Ratio

34.86%

Stock Overview

Market Cap

$22.90BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

110.70M

Volume

28.01K

Avg. Volume

868.87K

Financials (TTM)

Gross Profit

$3.75B

Operating Income

$1.61B

EBITDA

$2.12B

Operating Cash Flow

$1.85B

Capital Expenditure

-$524.00M

Free Cash Flow

$1.33B

Cash & ST Invst.

$393.00M

Total Debt

$6.98B

Quest Diagnostics Performance Analysis

Quest Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 9,883,000,000-8.4%
20232023-12-31USD 9,252,000,000-6.4%
20242024-12-31USD 9,872,000,0006.7%
20252025-12-31USD 11,035,000,00011.8%
Quest Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-304.1%
Q32025-09-302.0%
Q42025-12-31-0.4%
Q12026-03-313.2%
Quest Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 7.98-48.6%
20232023-12-31USD 7.52-5.8%
20242024-12-31USD 7.661.9%
20252025-12-31USD 8.7414.1%
Quest Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3027.3%
Q32025-09-30-12.6%
Q42025-12-310.9%
Q12026-03-312.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.90B

+9.2%

Gross Profit

$942.00M

+9.2%

Gross Margin

32.54%

N/A

Market Cap

$22.90BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$401.69K

N/A

Employees

57,000

N/A

Net Income

$252.00M

+14.5%

EBITDA

$434.00M

-11.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$393.00M

+109.0%

Total Debt

$6.98B

+6.2%

Accounts Receivable

$1.59B

+13.0%

Inventory

$225.00M

+19.0%

Long Term Debt

$6.30B

-1.5%

Short Term Debt

$677.00M

+289.1%

Return on Assets

6.14%

N/A

Return on Invested Capital

11.13%

N/A

Free Cash Flow

$164.00M

-16.8%

Operating Cash Flow

$278.00M

-11.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LHLabcorp Holdings Inc.
$279.90+0.18%
INCYIncyte Corporation
$116.64-0.64%
UTHRUnited Therapeutics Corporation
$529.19-1.24%
WATWaters Corporation
$371.76+1.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
ZCMDZhongchao
$5.54+2.77%
SOFISoFi Technologies
$17.16-0.03%
TET1 Energy Inc.
$6.12+0.00%
MARAMara Holdings
$12.50+0.02%

Questions About DGX

What is the current price of Quest Diagnostics?

Quest Diagnostics is trading at $207.60 per share.

What is the 52-week range for Quest Diagnostics?

Over the past 52 weeks, Quest Diagnostics has traded between $165.78 and $219.20.

How much debt does Quest Diagnostics have?

As of the most recent reporting period, Quest Diagnostics reported total debt of $6.41B.

How much cash does Quest Diagnostics have on hand?

Quest Diagnostics reported $393.00M in cash and cash equivalents in its most recent financial results.

What is Quest Diagnostics’s dividend yield?

Quest Diagnostics currently has a dividend yield of 1.61%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services